

SANTHERA PHARMACEUTICALS HOLDING AG

ISIN: CH1276028821 WKN: 127602882 Asset Class: Stock

Company

2024/07/17 17:30:08



Price

9.76 CHF

Difference ▲ 14.29%(1.22)



Contact Details

SANTHERA PHARMACEUTICALS
HOLDING AG

Tel: +41-61-906-89-50

--

Fax: +41-61-906-89-51

Hohenrainstrasse 24

Web:

<http://www.santhera.com>

4133 Pratteln

E-mail:

office@santhera.com

Company Profile

Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. Its product pipeline includes Vamorolone and Lonodelestat. The company was founded by Thomas Meier in 1998 and is headquartered in Pratteln, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	34,657,000		3,065,000		24,641,000	
Common stock capital		1,262,000		753,000		54,608,000
Fixed assets	74,972,000		60,661,000		66,476,000	
Equity capital of a company		59,943,000		-43,686,000		1,328,000
Cash and cash equivalents	30,370,000		1,353,000		21,208,000	
Accrued liabilities		3,858,000		26,805,000		4,794,000
Other assets	-		-		-	
Current liabilities		44,315,000		49,414,000		32,782,000
Prepayments and accrued income		-		-		-
Non-current liabilities		5,371,000		57,998,000		57,007,000
Different income		-		-		-
Other liabilities		0		4,335,000		20,491,000
Total assets	109,629,000	109,629,000	63,726,000	63,726,000	91,117,000	91,117,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	45	46	43
Equity ratio	54.68%	-68.55%	1.46%
Debt-equity ratio	82.89%	-245.87%	6,761.22%

Others

	2023	2022	2021
Tax Expense Rate	0.07%	-0.65%	-1.48%

SANTHERA PHARMACEUTICALS HOLDING AG

ISIN: CH1276028821 WKN: 127602882 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	103,414,000	7,473,000	-1,595,000
Net income	54,782,000	-71,076,000	-55,526,000
EBIT	77,458,198	-51,647,333	-39,221,739
Operating income before taxes	54,820,000	-70,616,000	-54,717,000
Cash Flow	47,271,000	-29,843,000	-37,359,000
Net interest income	-20,808,000	-20,189,000	-16,422,000
Research and development expenses	18,674,000	30,536,000	29,715,000
Income taxes	38,000	460,000	809,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	2,353,703	166,388	-37,991

Board of Directors

Otto Schwarz	Member of the administrative board
Shabir Hasham	Member of the administrative board
Bradley Meyer	Member of the administrative board
Philipp Gutzwiller	Member of the administrative board
Thomas Meier	Chairman of the administrative board

Members of Management Board

Dario Eklund	Chairman of Managing Board
Ana Vera	Member of Executive Committee
Andrew Smith	Member of Executive Committee
Geert Jan van Daal	Member of Executive Committee
Günther Metz	Member of Executive Committee
Neville Kodkani	Member of Executive Committee
Andreas Missy	Member of Executive Committee
Marc Schrader	Member of Executive Committee
Oliver Strub	Member of Executive Committee
Sabine Pilot	Member of Executive Committee
Sarah Holmes-Klotz	Member of Executive Committee